EN
Home/Answers/Long-term safety
ALLAll countries Side effects and safety

Are tirzepatide and semaglutide safe long term?

What we checked17 sources, each one opened and linked to the sentence it supportsLast checked Nov 16, 2026 · Next review due Nov 16, 2027 · How we write
The short answer

Trials followed tirzepatide (Mounjaro, Zepbound) and semaglutide (Ozempic, Wegovy) for about 3 to 4 years, so safety over longer use has not been measured. In semaglutide's 3-year heart trial, the US Wegovy label reports 16 in 100 stopped for side effects, against 8 in 100 on placebo. WHO calls long-term safety data limited. Labels warn of pancreatitis and gallbladder disease.

How long have tirzepatide and semaglutide been studied?

The longest trials we found ran about 3 to 4 years, so the effects of 10 or 20 years of use have not been measured.1,4,5

Semaglutide was first approved in the US in 2017, and tirzepatide in 2022, so real-world use of tirzepatide spans only a few years, according to their US labels.1,2

Semaglutide, SELECT. 17,604 adults with heart disease and no diabetes took Wegovy 2.4 mg or a dummy injection (placebo). They were followed for an average of 39.8 months.5 The US Wegovy label says people took Wegovy for a median of 37.3 months.2

Tirzepatide, SURMOUNT-1 and SURPASS-CVOT. SURMOUNT-1 gave tirzepatide or placebo for 176 weeks, about 3.4 years.4 SURPASS-CVOT compared Mounjaro with dulaglutide, an older weekly injection, in 13,299 adults with type 2 diabetes. It ran for a median of 210 weeks, about 4 years.1

The World Health Organization (WHO) made only a conditional recommendation for these medicines in December 2025. One reason it gives is "limited data on their long-term efficacy and safety".6

What side effects showed up over 3 to 4 years?

Stomach side effects were the most common, and more people stopped the medicine because of side effects than stopped the placebo.2,4

Tirzepatide. In SURMOUNT-1, stomach side effects were mostly mild to moderate. They came mainly in the first 20 weeks, while the dose was being raised. The authors found no new safety signals over the 3 years.4

Semaglutide. In SELECT, 16 in 100 people stopped Wegovy because of a side effect, against 8 in 100 on placebo, the US Wegovy label reports. In the same trial, a heart attack, stroke or death from heart disease happened in 6.5% on Wegovy and 8% on placebo.2

Eyes. In a 2-year trial in people with type 2 diabetes and high heart risk, complications of diabetic eye disease (retinopathy) occurred in 3.0% on Ozempic and 1.8% on placebo.3 The gap was larger in people who already had eye disease: 8.2% against 5.2%. The US Ozempic label says the long-term effect on this eye disease has not been studied.3

Damage to the eye's nerve (NAION) can cause sudden, painless loss of sight. The EU Wegovy label says large studies in type 2 diabetes link semaglutide with about 1 extra case per 10,000 people treated for a year.7

What long-term risks do the labels warn about?

The labels warn about thyroid tumours seen in rats, an inflamed pancreas and gallbladder disease, and they differ on who should not use these medicines.1,7,8

Thyroid. Tirzepatide caused thyroid C-cell tumours in rats. The US Mounjaro label says it is unknown whether it does so in humans.1

The US Mounjaro and Wegovy labels, and Canada's Zepbound and Wegovy labels, rule these medicines out after a personal or family history of medullary thyroid cancer. They also rule them out with MEN 2, an inherited condition that causes gland tumours.1,2,11,12 The EU and UK labels list only allergy to the medicine as a reason not to use it.7,8,9,10

Pancreas and gallbladder. An inflamed pancreas (pancreatitis) can cause severe belly pain that may spread to the back, the US Mounjaro label says. In its placebo-controlled trials, gallbladder problems such as gallstones hit 0.6% on Mounjaro and 0% on placebo.1

Stopping. In SURMOUNT-4, the weight of people switched from tirzepatide to placebo rose by 14.0% over the next year, while those who stayed on lost a further 5.5%.15 Your country's side effects guide, under "In your country" below, covers each risk in full.

What do people on GLP-1 medicines report about long-term safety?

From public patient forums: 54 Reddit threads in r/Zepbound, r/mounjarouk, r/Mounjaro, r/Semaglutide, r/Ozempic and r/WegovyWeightLoss, read from October 2025 to October 2026. Personal reports, not medical evidence.

What people describe

  • Matches the trial Many say stomach side effects such as nausea came early or after a dose rise, then settled.4
  • Matches the US label Many describe side effects that lasted for months or became serious. In SELECT, the US Wegovy label reports that 16 in 100 stopped Wegovy because of a side effect, against 8 in 100 on placebo.2
  • Matches the trial Many say their weight and hunger came back after stopping. A few report no regain after a short break, so accounts are mixed.15

Advice people share

  • WHO says otherwise Many argue that GLP-1 medicines have about 20 years of use, so late harms would have shown by now. Several reply that semaglutide and tirzepatide are newer. Tirzepatide was first approved in the US in 2022, and WHO calls long-term safety data limited.1,6
  • Matches the US label Several point out that the thyroid warning comes from rat studies. The US label rules these medicines out after a personal or family history of medullary thyroid cancer or MEN 2; the EU and UK labels do not.1,7,9
  • Matches the label Several advise regular check-ups. The US Ozempic label says people with diabetic eye disease should be monitored.3
  • WHO says otherwise Several mention splitting pens, changing the dosing gap or using unapproved products. WHO advises using these medicines as prescribed and avoiding unverified sources.16

In your country

The trial results are the same everywhere, but labels differ on whether a history of medullary thyroid cancer rules these medicines out.

Australia

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: none (Wegovy pill treated as not approved). Semaglutide tablets, diabetes: Rybelsus approved; whether supplied not confirmed.

Label: Australia's Wegovy label rules it out after a personal or family history of medullary thyroid cancer, or with MEN 2. Australia's Mounjaro label lists only allergy to the medicine.13,14

Emergency number: 000

Side effects and risks in Australia

Canada

Sold as: Tirzepatide: Mounjaro, Mounjaro KwikPen, Zepbound. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic; Semaglutide Injection (Dr. Reddy’s; shortage reported Jul 2026, lots recalled Aug 2026); Apo-Semaglutide (one lot recalled Aug 2026). Semaglutide tablets, weight: none (no oral Wegovy in Health Canada’s drug database). Semaglutide tablets, diabetes: Rybelsus. Semaglutide approved but not marketed: Sevmia, Poviztra, Plosbrio, Aspen-Semaglutide, Semaglutide Injection (Aspen), Sandoz Semaglutide.

Label: The answer above applies.

Emergency number: 911

Side effects and risks in Canada

France

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: none (Wegovy pill not sold in France). Semaglutide tablets, diabetes: none found (Rybelsus not in France’s medicines database).

Label: The EU Mounjaro and Wegovy labels list only allergy to the medicine as a reason not to use it. Unlike the US labels, they do not rule out use after medullary thyroid cancer.7,8

Emergency number: 15 or 112

Effets secondaires et risques en France

Germany

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy, including 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy Tablette. Semaglutide tablets, diabetes: Rybelsus.

Label: The EU Mounjaro and Wegovy labels list only allergy to the medicine as a reason not to use it. Unlike the US labels, they do not rule out use after medullary thyroid cancer.7,8

Emergency number: 112

Nebenwirkungen und Risiken in Deutschland

India

Sold as: Tirzepatide: Mounjaro, Yurpeak. Semaglutide injection, weight: Wegovy; Poviztra; Noveltreat. Semaglutide injection, diabetes: Ozempic; Obeda (Dr Reddy’s; recalled Jul 2026 over an active-ingredient impurity; on 23 Oct 2026 the company said it planned to relaunch in Nov; resumption not confirmed at 8 Nov 2026; distributors told Reuters it may be discontinued); Sematrinity; GLIPIQ; Semalix (batches recalled Jul 2026); Semanat; Semafull. Semaglutide injection, diabetes and weight: Semaglyn; Mashema; Alterme; Semasize; Obesema; Hepaglide. Semaglutide, diabetes and weight (form not confirmed): Obeda Pro; Obeda Plus (Dr Reddy’s, made by Hetero Labs; in the market from late Jul 2026). Semaglutide injection, use not confirmed: Semanext; Livarise; Sundae. Semaglutide, form and use not confirmed: Samakind; Usema (batches recalled). Semaglutide tablets, weight: not confirmed. Semaglutide tablets, diabetes: Rybelsus; Sembolic; Obeda (tablets not part of the Jul 2026 recall).

Label: We found no public Indian label, so this page relies on the US and EU labels, which differ on a history of medullary thyroid cancer.1,2,7,8

Emergency number: 112

Side effects and risks in India

Saudi Arabia

Sold as: Tirzepatide: Mounjaro, Mounjaro KwikPen. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic; Tasylev; Lugyda; Glucentra. Semaglutide tablets, weight: none (Wegovy pill not registered). Semaglutide tablets, diabetes: Rybelsus.

Label: We found no public Saudi label text to check, so this page relies on the US and EU labels, which differ on a history of medullary thyroid cancer.1,2,7,8

Emergency number: 997 or 911

الأعراض الجانبية والمخاطر في السعودية

United Arab Emirates

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy pill. Semaglutide tablets, diabetes: Rybelsus.

Label: We found no public UAE label text to check, so this page relies on the US and EU labels, which differ on a history of medullary thyroid cancer.1,2,7,8

Emergency number: 998 for an ambulance, or 999

Side effects and risks in the UAE

United Kingdom

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy, including 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy tablets (authorised 11 Jun 2026; retail sale not confirmed). Semaglutide tablets, diabetes: Rybelsus.

Label: The UK Mounjaro and Wegovy labels list only allergy to the medicine as a reason not to use it. Unlike the US labels, they do not rule out use after medullary thyroid cancer.9,10

Emergency number: 999

Side effects and risks in the UK

United States

Sold as: Tirzepatide: Zepbound, Mounjaro. Semaglutide injection, weight: Wegovy, including Wegovy HD 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy pill. Semaglutide tablets, diabetes: Ozempic tablets; Rybelsus (being discontinued).

Label: The answer above applies.

Emergency number: 911

Side effects and risks in the US

Get help now: call your local emergency number for severe belly pain or pressure, severe or persistent vomiting or diarrhoea, fainting, breathing problems, or sudden changes in vision.17 Emergency numbers: 911 in the US and Canada, 999 in the UK, 998 or 999 in the UAE, 000 in Australia, 112 in India and Germany, 15 or 112 in France, 997 or 911 in Saudi Arabia.

Contact your prescriber or a doctor right away if belly pain will not go away, sometimes spreading to the back, or if you notice a lump in the neck, trouble swallowing, shortness of breath or hoarseness that lasts.1 The EU Wegovy label says a sudden loss of vision needs an eye examination.7

Read the full picture

Related questions

Did this answer your question?

Sources

  1. Eli Lilly. Mounjaro (tirzepatide) injection: US prescribing information, boxed warning, section 4, warnings on thyroid tumours, pancreatitis and gallbladder disease (5.1, 5.8), and section 14.6 (SURPASS-CVOT). US label. pi.lilly.com
  2. Novo Nordisk. Wegovy (semaglutide) injection and tablets: US prescribing information, sections 4, 6 and 14.1 (cardiovascular outcomes trial). US label. novo-pi.com
  3. Novo Nordisk. Ozempic (semaglutide) injection: US prescribing information, section 5.3. US label. novo-pi.com
  4. Jastreboff AM et al. Tirzepatide for obesity treatment and diabetes prevention (SURMOUNT-1, 3 years). N Engl J Med 2025;392:958–71. Abstract read. doi:10.1056/NEJMoa2410819 · PubMed 39536238
  5. Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med 2023;389:2221–32. Funded by Novo Nordisk. Abstract read. doi:10.1056/NEJMoa2307563
  6. World Health Organization. WHO issues global guideline on the use of GLP-1 medicines in treating obesity, 1 December 2025. who.int
  7. European Medicines Agency. Wegovy (semaglutide): EU summary of product characteristics, sections 4.3, 4.4 and 4.8. EU label. ema.europa.eu
  8. European Medicines Agency. Mounjaro (tirzepatide): EU summary of product characteristics, section 4.3. EU label. ema.europa.eu
  9. Eli Lilly. Mounjaro KwikPen (tirzepatide): UK summary of product characteristics, section 4.3. UK label. medicines.org.uk
  10. Novo Nordisk. Wegovy 2.4 mg FlexTouch (semaglutide): UK summary of product characteristics, section 4.3. UK label. medicines.org.uk
  11. Eli Lilly Canada. Zepbound (tirzepatide injection): Canadian product monograph, contraindications. Canadian label. pdf.hres.ca
  12. Novo Nordisk Canada. Wegovy (semaglutide injection): Canadian product monograph, contraindications. Canadian label. pdf.hres.ca
  13. Eli Lilly. Mounjaro (tirzepatide): Australian Product Information, vA14.0, October 2026, section 4.3. Australian label. medsinfo.com.au
  14. Novo Nordisk. Wegovy (semaglutide): Australian Product Information, section 4.3. Australian label. medsinfo.com.au
  15. Aronne LJ et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity (SURMOUNT-4). JAMA 2024;331(1):38–48. Abstract read. doi:10.1001/jama.2023.24945
  16. World Health Organization. WHO issues warning on falsified medicines used for diabetes treatment and weight loss, 20 June 2024. who.int
  17. MedlinePlus (US National Library of Medicine). Recognizing medical emergencies, listing the American College of Emergency Physicians warning signs. Reviewed 8 January 2025. medlineplus.gov

Last checked Nov 16, 2026 · Next review due Nov 16, 2027 · Report an error

How this answer was made. Written by the GLP Guidebook team from the sources above, all checked on Nov 16, 2026. The “What people report” section summarises public patient forum posts we read; it is not medical evidence, and we never pass on advice that goes against the label. It’s general information, not medical advice. Talk to a doctor, pharmacist or other licensed prescriber before starting, stopping or changing any medicine. In an emergency, call your local emergency number. How we write